Lovenox weight calculator

Size: px
Start display at page:

Download "Lovenox weight calculator"

Transcription

1 P ford residence southampton, ny Lovenox weight calculator What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings I am so glad I decided to get the gastric sleeve. I struggled with my weight all my life,dealt with depression and anxiety. I was borderline diabetic and my July 25, Injected blood thinners don t prevent pregnancy complications in women who may be prone to blood clots, a. Useful Websites ClotCare provides the following links and descriptions because we think that these sites may be useful to you. ClotCare does not have an affiliation Events caused by sleep apnea and atrial fibrillation, two disorders that share many of the same risk factors and symptoms, can wake you up to a pounding. INTRODUCTION. Heparins, including unfractionated heparin and a variety of low molecular weight (LMW) heparin products, are used extensively as anticoagulants. Protamine dosing calculator for reversing

2 heparin and low molecular weight heparins The most commonly used injectable anticoagulants are heparin and low molecular weight heparins. Learn how much Vitamin K is in mustard with this interactive Nutrition Label. Adjustable portion sizes. Useful for Warfarin patients. An INR of 1.5 is considered low and can impact your Warfarin therapy. Use this interactive INR Tool to find out the causes and treatment for a 1.5 INR. Sep 24, obesity to enoxaparin dosing. Explain pharmacology of anticoagulation with enoxaparin if done outpatient. 09/01/10: Abdominal.. effect with uncapped dosing. Obese patients up to 159kg dosed by TBW [13]. Inverse correlation between anti- factor Xa levels and body weight. Obese pts might may. Detailed dosage guidelines and administration information for Lovenox ( enoxaparin sodium). Includes dose adjustments, warnings and precautions. Medscape - Indication-specific dosing for Lovenox (enoxaparin), frequency- based adverse effects, comprehensive interactions, contraindications, pregnancy. Low body weight (<45 kg for women or <57 kg for men): Increased exposure has been observed with prophylactic

3 (non-weight adjusted) dosage; carefully monitor. Mar 9, These data suggest that this weight-based regimen may be more effective than standard fixed-dose enoxaparin.. Serial measurements of anti-xa levels for area under the curve calculation were not feasible due to the frequency of peak values around 0.2 IU/mL or less, as the precision of the assay below. This tool allows you to calculate for adults the dose of enoxaparin(clexanetm) to the nearest whole syringe consistent with 2010 EKHUT guidance based on using egfr, the literature1,2,3 and the manufacturer's summary of product characteristics4 for the common adult indications for this low molecular weight heparin. Patients at extremes of weight should have the dose of enoxaparin adjusted and anticoagulation should be monitored using the low molecular weight heparin assay. In clinical trials using. To estimate the creatinine clearance (CrCl), first calculate the patients ideal body weight (IBW) in kg: Male: 50 kg (height in. Aug 2, rnity/1096.pdf. Prescribing guidance: -. Enoxaparin (a low molecular weight heparin) is prescribed according to indication and the patient's

4 weight and renal function. Patient's weight should be measured on admission and the weight documented on the drug chart and in the patient's nursing notes. The Weight Based Dose Calculator is used for weight based dosing. The parameters for the calculator include dosage, weight, med amount, per volume. [BMI <40 kg/m^2]: Dose: 30 mg SC q12h x7-10 days; Start: 12-24h postop; Alt: 40 mg SC qd x7-10 days, start 12h preop; Info: may cont. 40 mg SC qd x3wk as extended prophylaxis; D/C if Plt <100,000. [*BMI >40 kg/m^2]: Dose: 40 mg SC q12h; Start: 12-24h postop; Alt: 0.5 mg/kg SC q12-24h, use ABW to calculate dose;. The most commonly used injectable anticoagulants are heparin and low molecular weight heparins. Useful Websites ClotCare provides the following links and descriptions because we think that these sites may be useful to you. ClotCare does not have an affiliation. INTRODUCTION. Heparins, including unfractionated heparin and a variety of low molecular weight (LMW) heparin products, are used extensively as anticoagulants. Learn how much Vitamin K is in mustard with this interactive Nutrition Label. Adjustable portion sizes. Useful

5 for Warfarin patients. An INR of 1.5 is considered low and can impact your Warfarin therapy. Use this interactive INR Tool to find out the causes and treatment for a 1.5 INR. I am so glad I decided to get the gastric sleeve. I struggled with my weight all my life,dealt with depression and anxiety. I was borderline diabetic and my. Injected blood thinners don t prevent pregnancy complications in women who may be prone to blood clots, a new study shows. What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings Protamine dosing calculator for reversing heparin and low molecular weight heparins. WebMD: Congratulations on your baby! No matter what trimester, we want to hear all about your tests, ultrasounds, health team and of course the baby to come!. INTRODUCTION. Heparins, including unfractionated heparin and a variety of low molecular weight (LMW) heparin products, are used extensively as anticoagulants. I am so glad I decided to get the gastric sleeve. I struggled with my weight all my life,dealt with depression and anxiety. I was

6 borderline diabetic and my. What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings Protamine dosing calculator for reversing heparin and low molecular weight heparins. Learn how much Vitamin K is in mustard with this interactive Nutrition Label. Adjustable portion sizes. Useful for Warfarin patients The most commonly used injectable anticoagulants are heparin and low molecular weight heparins. Useful Websites ClotCare provides the following links and descriptions because we think that these sites may be useful to you. ClotCare does not have an affiliation Events caused by sleep apnea and atrial fibrillation, two disorders that share many of the same risk factors and symptoms, can wake you up to a pounding July 25, Injected blood thinners don t prevent pregnancy complications in women who may be prone to blood clots, a. An INR of 1.5 is considered low and can impact your Warfarin therapy. Use this interactive INR Tool to find out the causes and treatment for a 1.5 INR. Detailed dosage guidelines and

7 administration information for Lovenox ( enoxaparin sodium). Includes dose adjustments, warnings and precautions. Sep 24, obesity to enoxaparin dosing. Explain pharmacology of anticoagulation with enoxaparin if done outpatient. 09/01/10: Abdominal.. effect with uncapped dosing. Obese patients up to 159kg dosed by TBW [13]. Inverse correlation between anti- factor Xa levels and body weight. Obese pts might may. Patients at extremes of weight should have the dose of enoxaparin adjusted and anticoagulation should be monitored using the low molecular weight heparin assay. In clinical trials using. To estimate the creatinine clearance (CrCl), first calculate the patients ideal body weight (IBW) in kg: Male: 50 kg (height in. This tool allows you to calculate for adults the dose of enoxaparin(clexanetm) to the nearest whole syringe consistent with 2010 EKHUT guidance based on using egfr, the literature1,2,3 and the manufacturer's summary of product characteristics4 for the common adult indications for this low molecular weight heparin. Medscape - Indicationspecific dosing for Lovenox (enoxaparin), frequency- based

8 adverse effects, comprehensive interactions, contraindications, pregnancy. Low body weight (<45 kg for women or <57 kg for men): Increased exposure has been observed with prophylactic (non-weight adjusted) dosage; carefully monitor. [BMI <40 kg/m^2]: Dose: 30 mg SC q12h x7-10 days; Start: 12-24h postop; Alt: 40 mg SC qd x7-10 days, start 12h preop; Info: may cont. 40 mg SC qd x3wk as extended prophylaxis; D/C if Plt <100,000. [*BMI >40 kg/m^2]: Dose: 40 mg SC q12h; Start: 12-24h postop; Alt: 0.5 mg/kg SC q12-24h, use ABW to calculate dose;. Mar 9, These data suggest that this weight-based regimen may be more effective than standard fixed-dose enoxaparin.. Serial measurements of anti-xa levels for area under the curve calculation were not feasible due to the frequency of peak values around 0.2 IU/mL or less, as the precision of the assay below. Aug 2, rnity/1096.pdf. Prescribing guidance: -. Enoxaparin (a low molecular weight heparin) is prescribed according to indication and the patient's weight and renal function. Patient's weight should be measured on admission and the weight documented on the drug chart and in the patient's

9 nursing notes. The Weight Based Dose Calculator is used for weight based dosing. The parameters for the calculator include dosage, weight, med amount, per volume. Useful Websites ClotCare provides the following links and descriptions because we think that these sites may be useful to you. ClotCare does not have an affiliation. INTRODUCTION. Heparins, including unfractionated heparin and a variety of low molecular weight (LMW) heparin products, are used extensively as anticoagulants. What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings Protamine dosing calculator for reversing heparin and low molecular weight heparins. An INR of 1.5 is considered low and can impact your Warfarin therapy. Use this interactive INR Tool to find out the causes and treatment for a 1.5 INR. The most commonly used injectable anticoagulants are heparin and low molecular weight heparins. WebMD: Congratulations on your baby! No matter what trimester, we want to hear all about your tests, ultrasounds, health team and of course the baby to come!. I am so glad I

10 decided to get the gastric sleeve. I struggled with my weight all my life,dealt with depression and anxiety. I was borderline diabetic and my. Learn how much Vitamin K is in mustard with this interactive Nutrition Label. Adjustable portion sizes. Useful for Warfarin patients. Injected blood thinners don t prevent pregnancy complications in women who may be prone to blood clots, a new study shows. Useful Websites ClotCare provides the following links and descriptions because we think that these sites may be useful to you. ClotCare does not have an affiliation Events caused by sleep apnea and atrial fibrillation, two disorders that share many of the same risk factors and symptoms, can wake you up to a pounding The most commonly used injectable anticoagulants are heparin and low molecular weight heparins. Protamine dosing calculator for reversing heparin and low molecular weight heparins. What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings Learn how much Vitamin K is in mustard with this interactive Nutrition Label. Adjustable

11 portion sizes. Useful for Warfarin patients. I am so glad I decided to get the gastric sleeve. I struggled with my weight all my life,dealt with depression and anxiety. I was borderline diabetic and my. INTRODUCTION. Heparins, including unfractionated heparin and a variety of low molecular weight (LMW) heparin products, are used extensively as anticoagulants. An INR of 1.5 is considered low and can impact your Warfarin therapy. Use this interactive INR Tool to find out the causes and treatment for a 1.5 INR July 25, Injected blood thinners don t prevent pregnancy complications in women who may be prone to blood clots, a. [BMI <40 kg/m^2]: Dose: 30 mg SC q12h x7-10 days; Start: 12-24h postop; Alt: 40 mg SC qd x7-10 days, start 12h preop; Info: may cont. 40 mg SC qd x3wk as extended prophylaxis; D/C if Plt <100,000. [*BMI >40 kg/m^2]: Dose: 40 mg SC q12h; Start: 12-24h postop; Alt: 0.5 mg/kg SC q12-24h, use ABW to calculate dose;. Sep 24, obesity to enoxaparin dosing. Explain pharmacology of anticoagulation with enoxaparin if done outpatient. 09/01/10: Abdominal.. effect with uncapped dosing. Obese patients up to 159kg dosed by

12 TBW [13]. Inverse correlation between anti- factor Xa levels and body weight. Obese pts might may. This tool allows you to calculate for adults the dose of enoxaparin(clexanetm) to the nearest whole syringe consistent with 2010 EKHUT guidance based on using egfr, the literature1,2,3 and the manufacturer's summary of product characteristics4 for the common adult indications for this low molecular weight heparin. The Weight Based Dose Calculator is used for weight based dosing. The parameters for the calculator include dosage, weight, med amount, per volume. Medscape - Indication-specific dosing for Lovenox (enoxaparin), frequency- based adverse effects, comprehensive interactions, contraindications, pregnancy. Low body weight (<45 kg for women or <57 kg for men): Increased exposure has been observed with prophylactic (non-weight adjusted) dosage; carefully monitor. Detailed dosage guidelines and administration information for Lovenox ( enoxaparin sodium). Includes dose adjustments, warnings and precautions. Mar 9, These data suggest that this weight-based regimen may be more effective than standard fixed-dose

13 enoxaparin.. Serial measurements of anti-xa levels for area under the curve calculation were not feasible due to the frequency of peak values around 0.2 IU/mL or less, as the precision of the assay below. Aug 2, rnity/1096.pdf. Prescribing guidance: -. Enoxaparin (a low molecular weight heparin) is prescribed according to indication and the patient's weight and renal function. Patient's weight should be measured on admission and the weight documented on the drug chart and in the patient's nursing notes. Patients at extremes of weight should have the dose of enoxaparin adjusted and anticoagulation should be monitored using the low molecular weight heparin assay. In clinical trials using. To estimate the creatinine clearance (CrCl), first calculate the patients ideal body weight (IBW) in kg: Male: 50 kg (height in. WebMD: Congratulations on your baby! No matter what trimester, we want to hear all about your tests, ultrasounds, health team and of course the baby to come!. Injected blood thinners don t prevent pregnancy complications in women who may be prone to blood clots, a new study shows. Protamine

14 dosing calculator for reversing heparin and low molecular weight heparins. An INR of 1.5 is considered low and can impact your Warfarin therapy. Use this interactive INR Tool to find out the causes and treatment for a 1.5 INR. Learn how much Vitamin K is in mustard with this interactive Nutrition Label. Adjustable portion sizes. Useful for Warfarin patients. Useful Websites ClotCare provides the following links and descriptions because we think that these sites may be useful to you. ClotCare does not have an affiliation. The most commonly used injectable anticoagulants are heparin and low molecular weight heparins. INTRODUCTION. Heparins, including unfractionated heparin and a variety of low molecular weight (LMW) heparin products, are used extensively as anticoagulants. What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings I am so glad I decided to get the gastric sleeve. I struggled with my weight all my life,dealt with depression and anxiety. I was borderline diabetic and my. POST OFFICE BOX 3037 BRIDGEHAMPTON, NEW YORK PHONE: (631)

15 FAX: (631) home how to seperate the amphetamine from adderall 30mg synthroid dosage strengths, height and weight microsoft wallet card template pc printer reviews sample answer to a complaint for an eviction to ohio what dea schedule is flexeril on THIS PAGE WAS LAST UPDATE ON 04/13/01 COPYRIGHT 2000 Lovenox weight calculator ALL RIGHTS RESERVED

Anti- THrombosis with Enoxaparin in intubated Adolescents

Anti- THrombosis with Enoxaparin in intubated Adolescents Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question

More information

Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test.

Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. NHS GREATER GLASGOW AND CLYDE BOWEL SCREENING PROGRAMME Clinical Policy Guidelines Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. Date to

More information

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005 ANTICOAGULANT THERAPY REVISITED 2005 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most

More information

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy ~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular

More information

Enoxaparin sodium 150mg (equivalent to 15,000 IU anti-xa. activity) in 0.2ml water for injections. activity) in 0.4ml water for injections

Enoxaparin sodium 150mg (equivalent to 15,000 IU anti-xa. activity) in 0.2ml water for injections. activity) in 0.4ml water for injections 1. NAME OF THE MEDICINAL PRODUCT Clexane (Lovenox) Syringes Clexane (Lovenox) Forte Syringes 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Clexane (Lovenox) Syringes (100mg/ml) 20mg Injection 40mg Injection

More information

Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin

Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin Coordinated Primary Options Service DVT Management Plan Management options using Dabigatran or Warfarin Name NHI DOB Ethnicity Gender Address Contact Information Mobile Home Treatment commenced date *CPO

More information

Physician Orders - Adult

Physician Orders - Adult Physician Orders - Adult attach patient label here Title: Direct Thrombin Inhibitor (DTI) Protocol Orders Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy

More information

Analysis of the Anticoagulant Market

Analysis of the Anticoagulant Market MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS Analysis of the Anticoagulant Market VPG Publications, Consulting, Clients www.vpgcorp.com VPG Market Research Reports www.vpgmarketresearch.com

More information

DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes

DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes NHS ONEL & Barking, Havering & Redbridge University Hospitals Trust Shared Care Guidelines DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED

More information

ENOXAPARIN AHFS??? Class: Low molecular weight heparin (LMWH).

ENOXAPARIN AHFS??? Class: Low molecular weight heparin (LMWH). ENOXAPARIN AHFS??? Class: Low molecular weight heparin (LMWH). Indications: Prevention and treatment of deep vein thrombosis, pulmonary embolism, thrombophlebitis migrans, disseminated intravascular coagulation

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Clexane Syringes 100mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 20mg Injection 40mg Injection 60mg Injection

More information

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2 News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes

More information

Challenges of VTE Prophylaxis in. Orthopaedics. Prevalence of DVT in Orthopaedic Surgery Without Prophylaxis

Challenges of VTE Prophylaxis in. Orthopaedics. Prevalence of DVT in Orthopaedic Surgery Without Prophylaxis Grand Rounds Scripps Green Hospital May 5, 2010 Challenges of VTE Prophylaxis in Orthopaedics C. W. Colwell, Jr., M.D. At Scripps Clinic Challenges of VTE Prophylaxis in Orthopaedics I have a potential

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,

LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network, Lehigh Valley Health Network LVHN Scholarly Works Department of Pharmacy Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients

More information

Acknowledgements. Expert Panel. Medication Safety Support Service (MSSS) Advisory Group. Why Anticoagulant Safety? Anticoagulation Principles

Acknowledgements. Expert Panel. Medication Safety Support Service (MSSS) Advisory Group. Why Anticoagulant Safety? Anticoagulation Principles Ontario Medication Safety Support Service Anticoagulant Project Co-leads: Acknowledgements Carmine Stumpo, Toronto East General Hospital Kris Wichman, ISMP Canada Donna Walsh, ISMP Canada Funded by the

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clexane Multidose Vial 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Vials containing 300 mg enoxaparin (equivalent to 30,000 IU anti-xa

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clexane Forte Syringes 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pre-filled syringes: 120 mg Injection Enoxaparin sodium 120 mg (equivalent

More information

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Anticoagulants: Heparin. Oral anticoagulants.

More information

DOAC s and Implications on Laboratory Results. Kandice Kottke-Marchant, MD, PhD Cleveland Clinic

DOAC s and Implications on Laboratory Results. Kandice Kottke-Marchant, MD, PhD Cleveland Clinic DOAC s and Implications on Laboratory Results Kandice Kottke-Marchant, MD, PhD Cleveland Clinic Anticoagulants Heparin Low Molecular Weight Heparins enoxaparin, fragmin Heparin pentasaccharide - fondaparinux

More information

DATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

DATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION DATA SHEET 1 CLEXANE AND CLEXANE FORTE * 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CLEXANE Pre-filled syringes, ready-to-use: 20 mg injection enoxaparin sodium 20mg (equivalent to 2,000 IU anti-xa activity)

More information

Venous Thromboembolic Events (VTEs)

Venous Thromboembolic Events (VTEs) NURSING BEST PRACTICE GUIDE Venous Thromboembolic Events (VTEs) This document is one of the Myeloma Academy Nursing Best Practice Guides for the Management of Myeloma series. The purpose of this Guide

More information

Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey

Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research

More information

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Lu G, Deguzman FR, Hollenbach SJ, et al. Department of Biology, Portola Pharmaceuticals Inc.,

More information

Enoxaparin (Lovenox )

Enoxaparin (Lovenox ) What is enoxaparin (Lovenox )? Enoxaparin is also called Lovenox Enoxaparin is an anticoagulant, or blood thinner, that works to prevent blood clots from forming in your body or treat blood clots after

More information

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Apheresis Anticoagulant Removal Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Talk Outline Case presentation Factors associated with drug removal TPE s effects on hematologic parameters Anticoagulant properties

More information

MIIG INJECTABLE Graft The following languages are included in this packet:

MIIG INJECTABLE Graft The following languages are included in this packet: MIIG INJECTABLE Graft 128801-10 The following languages are included in this packet: English (en) Deutsch (de) Nederlands (nl) Français (fr) Español (es) Italiano (it) Português (pt) 中文 - Chinese (sch)

More information

BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular

BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular Medicine Cardiovascular Division Brigham and Women s Hospital

More information

newsletter november 06 Dr Peter Davidson, Pathologist in Charge Haematology

newsletter november 06 Dr Peter Davidson, Pathologist in Charge Haematology QML PATHOLOGY newsletter november 06 >> Low Molecular Weight Heparin (LMWH) Clinical Guidelines Dr Peter Davidson, Pathologist in Charge Haematology To aid the treating Doctor, we have devoted the November

More information

The importance of body size for bridging studies

The importance of body size for bridging studies The importance of body size for bridging studies Masato Kaneko, Takahiko Tanigawa, Ryosei Leo Kawai Clinical Sciences Japan, Bayer Yakuhin Ltd., Osaka, Japan ICH and guidelines related to bridging concept

More information

Use of Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolic Disease: Answers to Frequently Asked Questions

Use of Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolic Disease: Answers to Frequently Asked Questions Concise Review for Primary-Care Physicians Use of Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolic Disease: Answers to Frequently Asked Questions SCOTT C. LITIN, M.D., JOHN A. HEIT,

More information

Information about and Monitoring of Anticoagulant Therapy

Information about and Monitoring of Anticoagulant Therapy Warfarin (Coumadin) Indications for warfarin Treatment of arterial and venous thrombosis to prevent clot propagation Prevention of thromboembolic disease in thrombophilia, atrial fibrillation, mechanical

More information

Coagulation: The Ins and Outs. Sheila K. Coffman BSMT (ASCP)

Coagulation: The Ins and Outs. Sheila K. Coffman BSMT (ASCP) Coagulation: The Ins and Outs Sheila K. Coffman BSMT (ASCP) Coagulation Testing: What is it? Monitoring hemostasis Bleeding Clotting Coagulation Testing Monitoring therapy Heparin Monitor with ACT / aptt

More information

UPDATE ON SPECIFIC ANTIDOTES FOR TARGET-SPECIFIC ORAL ANTICOAGULANTS

UPDATE ON SPECIFIC ANTIDOTES FOR TARGET-SPECIFIC ORAL ANTICOAGULANTS UPDATE ON SPECIFIC ANTIDOTES FOR TARGET-SPECIFIC ORAL ANTICOAGULANTS Junporn Kongwatcharapong (Pharm. D.) Clinical Pharmacist, Siriraj Hospital OUTLINE Introduction Approach to the management of TSOACs

More information

Initial Dose 10,000 units Every 4 to 6 hours 5,000 to 10,000 units. Intermittent IV injection

Initial Dose 10,000 units Every 4 to 6 hours 5,000 to 10,000 units. Intermittent IV injection HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HEPARIN SODIUM IN 0.45% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information

More information

Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request

Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin

More information

Mark Crowther, MD, MSc, FRCPC. Co-authors. Professor of Medicine, McMaster University, Canada

Mark Crowther, MD, MSc, FRCPC. Co-authors. Professor of Medicine, McMaster University, Canada Reversal of Enoxaparin-Induced Anticoagulation in Healthy Subjects by Andexanet Alfa (PRT064445), An Antidote for Direct and Indirect fxa Inhibitors A Phase 2 Randomized, Double-Blind, Placebo Controlled

More information

MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication

MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication Guide each time you get more ribavirin tablets. There may

More information

New Anticoagulants. Kenneth A. Bauer

New Anticoagulants. Kenneth A. Bauer New Anticoagulants Kenneth A. Bauer Traditional anticoagulant drugs, including unfractionated heparin and warfarin, have several limitations. New anticoagulants have been developed that target a single

More information

Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources

Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep Mark Crowther on behalf many Some slides modified from other sources 1 Disclosures Major disclosure: Paid consulting with Portola,

More information

Clinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for

More information

Coagulation in perspective: Blood management. Objectives

Coagulation in perspective: Blood management. Objectives Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.

More information

Marcia L. Zucker, Ph.D. ZIVD LLC

Marcia L. Zucker, Ph.D. ZIVD LLC Marcia L. Zucker, Ph.D. ZIVD LLC 1 Monitoring hemostasis Bleeding Clotting 2 Picture courtesy of Helena Laboratories 3 Extrinsic Pathway Monitor with ACT / aptt WARFARIN Monitor with PT Common Pathway

More information

GUIDANCE DOCUMENT Product Monograph

GUIDANCE DOCUMENT Product Monograph GUIDANCE DOCUMENT Published by authority of the Minister of Health Adopted Date 2016/06/17 Revised Date 2016/12/09 Effective Date 2017/06/09 Health Products and Food Branch Our mission is to help the people

More information

Anticoagulant therapy has historically consisted. A pharmacologic overview of current and emerging anticoagulants

Anticoagulant therapy has historically consisted. A pharmacologic overview of current and emerging anticoagulants A pharmacologic overview of current and emerging anticoagulants EDITH A. NUTESCU, PHARMD; NANCY L. SHAPIRO, PHARMD; AIMEE CHEVALIER, PHARMD; AND ALPESH N. AMIN, MD, MBA ABSTRACT For over 50 years, anticoagulant

More information

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects. Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated

More information

Alex C. Spyropoulos, MD; Judith S. Hurley, MS, RD; Gabrielle N. Ciesla, MS; and Gregory de Lissovoy, PhD, MPH

Alex C. Spyropoulos, MD; Judith S. Hurley, MS, RD; Gabrielle N. Ciesla, MS; and Gregory de Lissovoy, PhD, MPH Management of Acute Proximal Deep Vein Thrombosis* Pharmacoeconomic Evaluation of Outpatient Treatment With Enoxaparin vs Inpatient Treatment With Unfractionated Heparin Alex C. Spyropoulos, MD; Judith

More information

Cancer Vanguard. Biosimilars Trust Policy Template

Cancer Vanguard. Biosimilars Trust Policy Template Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars

More information

Heparin-induced thrombocytopenia (HIT) and

Heparin-induced thrombocytopenia (HIT) and Clinical Outcomes After Conversion from Low-Molecular-Weight Heparin to Unfractionated Heparin for Venous Thromboembolism Prophylaxis Kip Waite, BA, Jane Rhule, RN, CPHQ, and Barry R. Meisenberg, MD Abstract

More information

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY

More information

Revolutionizing the Treatment of Infectious Diseases with Defensin-Mimetics

Revolutionizing the Treatment of Infectious Diseases with Defensin-Mimetics www.polymedix.com Revolutionizing the Treatment of Infectious Diseases with Defensin-Mimetics Ticker: PYMX March 2012 Disclaimer and Safe Harbor Forward-looking statements This presentation contains forward-looking

More information

Timing the First Postoperative Dose of Anticoagulants Lessons Learned From Clinical Trials

Timing the First Postoperative Dose of Anticoagulants Lessons Learned From Clinical Trials [ Commentary ] Timing the First Postoperative Dose of Anticoagulants Lessons Learned From Clinical Trials Jeremy S. Paikin, MD ; Jack Hirsh, MD ; Noel C. Chan, MBBS ; Jeffrey S. Ginsberg, MD ; Jeffrey

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

HEMOCHRON. Whole Blood Coagulation Systems

HEMOCHRON. Whole Blood Coagulation Systems HEMOCHRON Whole Blood Coagulation Systems Activated Partial Thromboplastin Time (APTT) Cuvette Correlation Protocol for HEMOCHRON Microcoagulation Instruments MSIG: 49 10/06 Dear Medical Professional:

More information

VALIDATION GUIDE FOR CHROMOGENIC ASSAY FOR ACTIZYME Anti-FIIa

VALIDATION GUIDE FOR CHROMOGENIC ASSAY FOR ACTIZYME Anti-FIIa VALIDATION GUIDE FOR CHROMOGENIC ASSAY FOR ACTIZYME Anti-FIIa Chromogenic assay for testing heparins (UFH, LMWH and Enoxaparin) in purified systems by measurement of FIIa Inhibition, in compliance with

More information

Peer Review Report # 2. Low Molecular Weight Heparins

Peer Review Report # 2. Low Molecular Weight Heparins 20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report # 2 Low Molecular Weight Heparins (1) Does the application adequately address the issue of the public health need for

More information

Sovaldi Pegasys Ribavirin

Sovaldi Pegasys Ribavirin Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Sovaldi Pegasys

More information

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this

More information

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician.

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician. TM CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician. TABLE OF CONTENTS Section Port Styles 4 Description 5 Indications 5 Contraindications 5-6 Information

More information

Parenteral Anticoagulants

Parenteral Anticoagulants CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based

More information

DRUG DEVELOPMENT TARGET PRODUCT PROFILE

DRUG DEVELOPMENT TARGET PRODUCT PROFILE DRUG DEVELOPMENT TARGET PRODUCT PROFILE Template This template provides suggested considerations that may assist biopharmaceutical companies in their decisions as to whether to proceed with a drug development

More information

Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1

Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1 Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1 Donna D. Castellone, MS, MT (ASCP) SH Clinical Project Manager Hematology and Hemostasis Siemens Healthcare Diagnostics Disclosures

More information

The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital*

The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital* CHEST The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital* Maureen A. Smythe, PharmD, FCCP; John M. Koerber, PharmD; and Joan C. Mattson, MD Original

More information

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs) GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs) DRAFT GUIDANCE This guidance document is for feedback purposes only Comments and suggestions regarding this draft document should be submitted within

More information

Betrixaban (Bevyxxa) A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor

Betrixaban (Bevyxxa) A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor Betrixaban (Bevyxxa) A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor Jessica W. Skelley, PharmD, BCACP; Angela R. Thomason, PharmD, BCPS; and Jeffery C. Nolen, PharmD Candidate INTRODUCTION Venous

More information

uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B

uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection

Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical

More information

New Drug Evaluation: Betrixaban Capsules

New Drug Evaluation: Betrixaban Capsules Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for

More information

The PREDICT Program at Vanderbilt : Four Drug Gene Interactions and Counting

The PREDICT Program at Vanderbilt : Four Drug Gene Interactions and Counting The PREDICT Program at Vanderbilt : Four Drug Gene Interactions and Counting Michael Laposata, MD, PhD Fody Professor of Pathology Professor of Medicine Pathologist in Chief Vanderbilt University Hospital

More information

Antithrombin Deficiency

Antithrombin Deficiency Stop the Clot TM Antithrombin Deficiency An In-Depth Guide for Patients and Health Care Providers www.stoptheclot.org AWARENESS PREVENTION TREATMENT SUPPORT NATT Mission To prevent, diagnose and treat

More information

Molecular Diagnostics. Castle Medical LLC.

Molecular Diagnostics. Castle Medical LLC. Molecular Diagnostics Castle Medical LLC. What is DNA testing? Pharmacogenomics is a scientific disciple that deals with the influence of patient s genotype on drug response. Objective: to deliver the

More information

Introduction. This booklet also highlights ways to minimise the potential risks associated with micafungin use.

Introduction. This booklet also highlights ways to minimise the potential risks associated with micafungin use. 1 2 Introduction This booklet for prescribers and nurses provides practical guidance on the safe use and administration of micafungin, an echinocandin antifungal drug. This booklet also highlights ways

More information

Session 7 Clinical Trial Assessment Bioequivalence Studies

Session 7 Clinical Trial Assessment Bioequivalence Studies L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label

More information

REGULATORY LABELLING REQUIREMENTS AND ITS COMPARISON IN USA AND CANADA

REGULATORY LABELLING REQUIREMENTS AND ITS COMPARISON IN USA AND CANADA WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Krupa et al. SJIF Impact Factor 2.786 Volume 4, Issue 3, 799-810. Research Article ISSN 2278 4357 Article Received on 13 Dec 2014, REGULATORY LABELLING

More information

Canine Creatinine(Cr) ELISA kit. Catalog No. MBS (96T)

Canine Creatinine(Cr) ELISA kit. Catalog No. MBS (96T) Canine Creatinine(Cr) ELISA kit Catalog No. MBS704078 (96T) This immunoassay kit allows for the in vitro quantitative determination of canine Cr concentrations in serum, plasma and other biological fluids.

More information

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary

More information

Tranexamic Acid in Joint Replacement Surgery. Donna Berta Blood Conservation Program Coordinator

Tranexamic Acid in Joint Replacement Surgery. Donna Berta Blood Conservation Program Coordinator Tranexamic Acid in Joint Replacement Surgery Donna Berta Blood Conservation Program Coordinator Today s Objectives After this presentation participants will be able to: to describe the basic physiology

More information

Massive Haemorrhage J Davies B Ferguson

Massive Haemorrhage J Davies B Ferguson Massive Haemorrhage J Davies B Ferguson What is Massive Haemorrhage (MH)? Difficult to apply rules as to how much blood loss defines a major haemorrhage. Easier to define how the patient s condition is

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED AND RECOMBINANT COAGULATION FACTOR IX PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED AND RECOMBINANT COAGULATION FACTOR IX PRODUCTS The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 29 June 2000 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 19 July 2007 CPMP/BPWG/1561/99 rev.1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE

More information

CLINICAL TRIALS AND MARKET RESEARCH

CLINICAL TRIALS AND MARKET RESEARCH CLINICAL TRIALS AND MARKET RESEARCH AAKP's role in Clinical Trials and Market Research AAKP supports innovation in the kidney space. We are actively involved in market research - to share the patient voice

More information

Renal Dialysis Services

Renal Dialysis Services INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Renal Dialysis Services L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 4 5 P U B L I S H E D : N O V E M B E R 1 6, 2 0 1 7

More information

Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism In Patients With Cancer

Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism In Patients With Cancer Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-15-2009 Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism In Patients

More information

Insight to Gene Techno Science Co.,Ltd

Insight to Gene Techno Science Co.,Ltd Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed

More information

OMNITROPE (somatropin [rdna origin]) for injection DESCRIPTION

OMNITROPE (somatropin [rdna origin]) for injection DESCRIPTION 1 OMNITROPE (somatropin [rdna origin]) for injection DESCRIPTION OMNITROPE (somatropin [rdna origin]) for injection is a polypeptide hormone of recombinant DNA origin. It has 191 amino acid residues and

More information

Heparin: Powerful and Instantaneously acting Anticoagulant

Heparin: Powerful and Instantaneously acting Anticoagulant 30 Review Article Heparin: Powerful and Instantaneously acting Anticoagulant Amitava Sinha Ray* Ranbaxy Laboratories Ltd West Bengal, India *a.amitava.s@gmail.com ABSTRACT Anticoagulantis an agent that

More information

Heparin Drip And Ptt Chart

Heparin Drip And Ptt Chart Heparin Drip And Ptt Chart Free PDF ebook Download: Heparin Drip And Ptt Chart Download or Read Online ebook heparin drip and ptt chart in PDF Format From The Best User Guide Database Feb 1, 2011 - Discontinue

More information

Low-Molecular-Weight-Heparin as Thromboprophylaxis: a Dosage Problem in Obese Patients

Low-Molecular-Weight-Heparin as Thromboprophylaxis: a Dosage Problem in Obese Patients IBIMA Publishing Journal of Research in Obesity http://www.ibimapublishing.com/journals/obes/obes.html Vol. 2014 (2014), Article ID 282504, 8 pages DOI: 10.5171/2014.282504 Research Article Low-Molecular-Weight-Heparin

More information

Pharmacoepidemiology. Dr. Mahyar Etminan Scientist Department of Medicine, UBC

Pharmacoepidemiology. Dr. Mahyar Etminan Scientist Department of Medicine, UBC Pharmacoepidemiology Dr. Mahyar Etminan Scientist Department of Medicine, UBC Contacts Email: metminan@shaw.ca Tel: 604-875-2000 (7954) What is pharmacoepidemiology? study of drug efficacy, toxicity and

More information

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) 1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous

More information